TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Isofol Medical AB ( (SE:ISOFOL) ) just unveiled an update.
Isofol Medical AB announced that the European Patent Office intends to grant a new product patent for its cancer drug candidate, arfolitixorin, which will provide protection until 2043. This patent strengthens Isofol’s intellectual property portfolio, supporting the long-term development and commercialization of arfolitixorin, and increases the project’s value. The patent will cover pharmaceutical compositions comprising arfolitixorin in stable lyophilizate form, and the company plans to pursue additional patent protection in key regions such as the US and Japan.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on improving treatments for severe forms of cancer. The company’s primary product, arfolitixorin, is a drug candidate designed to enhance the efficacy of standard cancer treatments, particularly for solid tumors. Isofol is currently conducting clinical trials for arfolitixorin in metastatic colorectal cancer, aiming to address the high medical need for better treatments in this area.
Average Trading Volume: 607,355
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK195.5M
Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.